Professor Abila brings extensive experience in clinical drug development.

Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect.

Professor Abila has over 15 years’ experience in clinical medicine and academic medical research, and over 26 years’ experience in clinical drug development. His experiences includes the development and use of translation biomarkers to facilitate decision-making during early clinical drug development and for differentiation of medicines post-marketing authorisation. He most recently served as CMO for Cmed, a technology-led contract research organization (CRO) conducting oncology clinical trials. Alongside that, he was the principle consultant at Clintreq, providing drug development services to various companies focused on biologics. He previously held senior global clinical drug development and leadership roles in Aventis, Pfizer, Astellas, AstraZeneca and, most recently, GSK.

Professor Abila was appointed as a Visiting Professor of Biologics and Advanced Therapy Drug Development to the Faculty of Life Sciences & Medicine at King’s College London in 2015. He has published over 30 papers in peer-reviewed journals as well as multiple abstracts for scientific meetings and co-authored several patents. He has earned his Doctorate in Medicine from the University of Ibadan, Nigeria and further earned a Doctorate in Medicine & Clinical Pharmacology from the University of Wales. He is a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).

Dr Jaap Kampinga, Chief Executive of Immodulon, commented:
“We are very pleased to welcome Professor Abila to Immodulon as our new Chief Medical Officer. Bams has extensive knowledge and critical insight on drug development. As an experienced CMO, his record will be invaluable to Immodulon as we continue to further advance our lead candidate, IMM-101, and I look forward to working closely with him.”

About Immodulon Therapeutics
Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system by several mechanisms, including via Toll-like receptors. Its mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and other standard-of-care treatments, it is expected to enhance their efficacy without increasing the safety burden for the patient. For more information about Immodulon, please visit